公开(公告)号：US20180008458A1

公开(公告)日：2018-01-11

申请号：US15539565

申请日：2015-04-30

Applicant: Cell Cure Neurosciences Ltd.

Inventor： Eyal Banin ,  Benjamin Eithan Reubinoff ,  Osnat Bohana-Kashtan ,  Nir Netzer ,  Charles Sherard Irving

IPC: A61F9/00 ,  A61F9/007 ,  A61K35/30 ,  C12N5/079 ,  A61K38/17 ,  A61K35/12

CPC classification number: A61F9/0008 ,  A61F9/00727 ,  A61K35/30 ,  A61K38/1709 ,  A61K2035/124 ,  C12N5/0621

Abstract: A method of treating a subject with dry-form age-related macular degeneration (AMD) is disclosed. The method comprises administering into the subretina of the subject a therapeutically effective amount of a pharmaceutical composition comprising human RPE cells, wherein at least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms to the subject, thereby treating the subject.

公开(公告)号：US20230028133A1

公开(公告)日：2023-01-26

申请号：US17943462

申请日：2022-09-13

Applicant: CELL CURE NEUROSCIENCES LTD.

Inventor： Eyal Banin ,  Benjamin Eithan Reubinoff ,  Osnat Bohana-Kashtan ,  Nir Netzer ,  Charles Sherard Irving

IPC: A61F9/00 ,  A61K38/17 ,  A61F9/007 ,  A61K35/30 ,  C12N5/079 ,  A61K35/12

Abstract: A method of treating a subject with dry-form age-related macular degeneration (AMD) is disclosed. The method comprises administering into the subretina of the subject a therapeutically effective amount of a pharmaceutical composition comprising human RPE cells, wherein at least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), and wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms to the subject, thereby treating the subject.